Table 1: Etiology of OA
Table 2: Genes Associated with OA and Joint Development
Table 3: Signs and Symptoms of OA
Table 4: Hand, Knee, and Hip OA Severity Scoring System Using the Kellgren-Lawrence Scale
Table 5: Risk Factors and Comorbidities for OA
Table 6: Global Estimates for the Diagnosed Prevalence of OA
Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast for Hand OA Total Prevalent Cases
Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of Knee OA Total Prevalent Cases
Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast of Hip OA Total Prevalent Cases
Table 10: 7MM, Sources of Epidemiological Data Used for the Forecast of Hand OA Diagnosed Prevalent Cases
Table 11: 7MM, Sources of Epidemiological Data Used for the Forecast of Knee OA Diagnosed Prevalent Cases
Table 12: 7MM, Sources of Epidemiological Data Used for the Forecast of Hip OA Diagnosed Prevalent Cases
Table 13: 7MM, Sources of Epidemiological Data Used for the Severity* of Knee OA Based on KL Grade
Table 14: 7MM, Total Prevalent Cases of Hand OA, Both Sexes, Ages =20 Years, N, 2014–2024
Table 15: 7MM, Age-Specific Total Prevalent Cases of Hand OA, Both Sexes, N (Row %), 2014
Table 16: 7MM, Sex-Specific Total Prevalent Cases of Hand OA, Ages =20 Years, N (Row %), 2014
Table 17: 7MM, Total Prevalent Cases of Knee OA, Both Sexes, Ages =20 Years, N, 2014–2024
Table 18: 7MM, Age-Specific Total Prevalent Cases of Knee OA, Both Sexes, N (Row %), 2014
Table 19: 7MM, Sex-Specific Total Prevalent Cases of Knee OA, Ages =20 Years, N (Row %), 2014
Table 20: 7MM, Total Prevalent Cases of Hip OA, Both Sexes, Ages =20 Years, N, 2014–2024
Table 21: 7MM, Age-Specific Total Prevalent Cases of Hip OA, Both Sexes, N (Row %), 2014
Table 22: 7MM, Sex-Specific Total Prevalent Cases of Hip OA, Ages =20 Years, N (Row %), 2014
Table 23: 7MM, Diagnosed Prevalent Cases of Hand OA, Both Sexes, Ages =20 Years, N, 2014–2024
Table 24: 7MM, Age-Specific Diagnosed Prevalent Cases of Hand OA, Both Sexes, N (Row %), 2014
Table 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hand OA, Ages =20 Years, N (Row %), 2014
Table 26: 7MM, Diagnosed Prevalent Cases of Knee OA, Both Sexes, Ages =20 Years, N, 2014–2024
Table 27: 7MM, Age-Specific Diagnosed Prevalent Cases of Knee OA, Both Sexes, N (Row %), 2014
Table 28: 7MM, Sex-Specific Diagnosed Prevalent Cases of Knee OA, Ages =20 Years, N (Row %), 2014
Table 29: 7MM, Diagnosed Prevalent Cases of Hip OA, Both Sexes, Ages =20 Years, N, 2014–2024
Table 30: 7MM, Age-Specific Diagnosed Prevalent Cases of Hip OA, Both Sexes, N (Row %), 2014
Table 31: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hip OA, Ages =20 Years, N (Row %), 2014
Table 32: 7MM, Total and Diagnosed Prevalent Cases of Knee OA by Severity Based on KL Grades, Both Sexes, Ages =20 Years, N, 2014
Table 33: Overview of Leading NSAIDs for OA Treatment
Table 34: Efficacy of NSAIDs in OA Studies
Table 35: SWOT Analysis – NSAIDs, 2015
Table 36: Overview of the Leading Topical Therapies for OA, 2015
Table 37: Efficacy of Topical Therapies in OA
Table 38: SWOT Analysis – Topical Treatments, 2015
Table 39: Overview of the Leading Opioids for OA Treatment
Table 40: Studies Evaluating the Efficacy of Opioids in OA
Table 41: SWOT Analysis – Opioids, 2015
Table 42: Overview of the Leading Antidepressants for OA Treatment, 2015
Table 43: Overview of the Leading IA Corticosteroid Injectables for OA Treatment, 2015
Table 44: Efficacy of IA Corticosteroid Injectables in OA Studies
Table 45: SWOT Analysis – IA Steroid Injections in OA
Table 46: Unmet Needs in OA
Table 47: Clinical Trial Design of Key Pipeline Drugs for OA, 2015
Table 48: OA – Promising Drugs in Clinical Development, 2015
Table 49: Product Profile – Ampion
Table 50: Phase III (SPRING): Efficacy of Ampion in Patients with Knee OA at Week 12
Table 51: Phase III (SPRING Extension): Efficacy of Ampion in Patients with Moderate-to-Severe Knee OA at Week 12
Table 52: Ampion SWOT Analysis
Table 53: Product Profile – NKTR-181
Table 54: NKTR-181 SWOT Analysis, 2015
Table 55: Product Profile – FX006
Table 56: Phase IIb: Efficacy of FX006 in Patients with Moderate-to-Severe Knee OA at Week 12
Table 57: FX006 SWOT Analysis, 2015
Table 58: Product Profile – Tanezumab
Table 59: Phase III: Efficacy of Tanezumab in Patients with Knee or Hip OA
Table 60: Phase III: Efficacy of Tanezumab in Patients with Knee or Hip OA in Multiple Studies
Table 61: Tanezumab SWOT Analysis
Table 62: Product Profile – Fasinumab
Table 63: Phase II Efficacy of Fasinumab in Patients with Hip or Knee OA
Table 64: Fasinumab SWOT Analysis, 2015
Table 65: Product Profile – Invossa
Table 66: Phase IIb: Efficacy of Invossa in Patients with Knee OA
Table 67: Invossa SWOT Analysis, 2015
Table 68: Product Profile – Sprifermin
Table 69: Phase IIb: Efficacy of Sprifermin in Patients with Knee OA (at 12 Months)
Table 70: Sprifermin SWOT Analysis, 2015
Table 71: Early-Stage Pipeline Products for OA as of July 2015
Table 72: Clinical Benchmarking for OA
Table 73: Clinical Benchmarking for OA
Table 74: Top-Line Sales Forecast ($m) for OA, 2014–2024
Table 75: Key Events that Will Impact Sales for OA, 2014–2024
Table 76: Global OA Market – Drivers and Barriers, 2014–2024
Table 77: Key Launch Dates
Table 78: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country